This Page

has moved to a new address:

 Academic Life in Emergency Medicine: MIA 2012: IST-3 collaborative group et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012 Jun 23;379(9834):2352-63.

Sorry for the inconvenience…

Redirection provided by Blogger to WordPress Migration Service